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Abstract Biallelic pathogenic variants in RAB3GAP2 cause Warburg Micro syndrome
(WARBM) andMartsolf syndrome (MS), two rare, phenotypically overlapping disorders char-
acterized by congenital cataracts, intellectual disability, and hypogonadism. Although the
initial report documented hypergonadotropic hypogonadism (implying a gonadal defect),
an adolescent girl with WARBM/MS was subsequently reported to have hypogonadotropic
hypogonadism (implying a central defect in either the hypothalamus or anterior pituitary).
However, in adult MS, hypogonadotropism has not been convincingly demonstrated.
Additionally, the correlation between the pathogenic severity of variants in RAB3GAP2
and the phenotypic severity also remains unclear. Here we present a clinical report of a
woman with congenital cataracts, apparent intellectual disability, and pubertal failure
who underwent exome sequencing (ES) to determine a precise molecular diagnosis.
Reproductive phenotypes reported previously in individuals with MS and the genotypic
spectrum of previous RAB3GAP2 variants were also reviewed. The ES identified pathogenic
compound heterozygous RAB3GAP2 variants (c.387-2A>G; p.(Arg428Glu)) combinedwith
her phenotypic features, which enabled a unifyingmolecular diagnosis of MS. Reproductive
evaluation confirmed a normosmic idiopathic hypogonadotropic hypogonadism. Review of
the RAB3GAP2 allelic spectrum in WARBM/MS suggests that although variants resulting in
complete abrogation of RAB3GAP2 protein function cause severe WARBM, variants asso-
ciated with partially preserved RAB3GAP2 function cause milder MS. This report expands
the genotypic and phenotypic spectrum of MS and demonstrates hypogonadotropic hypo-
gonadism as a key pathophysiologic abnormality in MS. Genotype–phenotype associations
of previously reported RAB3GAP2 variants indicate that variants that fully abolish
RAB3GAP2 function result in WARBM, whereas MS is associated with variants of lesser
severity with residual RAB3GAP2 function.
[Supplemental material is available for this article.]
INTRODUCTION
Warburg Micro syndrome (WARBM; MIM614225) and Martsolf syndrome (MS; MIM212720)
represent the severe andmild forms, respectively, of a clinical syndrome characterized by the
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association of congenital cataracts, microcephaly, intellecutual disability, and hypogonad-
ism (Aligianis et al. 2006; Borck et al. 2011). Compared to the WARBM phenotype, individ-
uals with MS lack optic atrophy; have less severe functional visual impairment; do not have
polymicrogyria or corpus callosal defects on brain imaging; have milder intellectual disabil-
ity; and have muscular spasticity restricted to their lower limbs. Four genes (RAB3GAP1,
RAB3GAP2, RAB18, and TBC1D20) are associated with WARBM/MS. Pathogenic variants
in these genes result in dysfunctions of a RAB18, a GTPase, either directly (RAB18) or indi-
rectly (RAB3GAP1, RAB3GAP2, TBC1D20) (Handley et al. 2013; Handley and Sheridan
2018) and in RAB18 dysregulation and are thus believed to contribute to the disease pathol-
ogy in both WARBM and MS via disruptions of these biologic pathways.
Although hypogonadism is a key feature in the WARBM/MS spectrum, most reproduc-
tive phenotypes in individuals with WARBM/MS (Sánchez et al. 1985; Hennekam et al.
1988; Harbord et al. 1989; Aligianis et al. 2006; Handley et al. 2013; Gumus 2018;
Handley and Sheridan 2018) have only been ascertained prepubertally (i.e., in infancy or pre-
puberty) and longitudinal studies regarding pubertal transition in these patients are also
lacking. In addition, there is contradictory information regarding the nature of the hypogo-
nadism (i.e., primary vs. secondary) in the handful of clinical reports involving adolescent/
adult patients. In the initial report, two adult males had hypergonadotropism but with normal
serum testosterone levels, suggestive of a compensated state of primary hypogonadism (i.e.,
a gonadal defect) (Martsolf et al. 1978). In contrast, a 17-yr-old prepubertal female with MS
and primary amenorrhea was subsequently reported who had hypogonadotropic hypogo-
nadism (Hennekam et al. 1988), suggesting secondary hypogonadism (i.e., a defect in hypo-
thalamus and/or anterior pituitary). Unfortunately, genetic studies were not included in these
prior reports. Herein, we describe a genotype-guided study that identified novel pathogenic
variants in RAB3GAP2 in an adult patient fulfilling clinical criteria for MS with complete ab-
sence of puberty and hypogonadotropic hypogonadism (suggesting underlying hypotha-
lamic and/or pituitary defect) associated with RAB3GAP2-related MS.
RESULTS
Clinical Presentation and Family History
A female proband, born to nonconsanguineous parents, presented at 2 wk of age with bilat-
eral cataracts and underwent lensectomies and subsequent strabismus repair. In late infancy,
she was also noted to have hearing difficulties. Initially, the proband attended a school for
visually impaired and, upon recognition of moderate learning difficulties, was transferred
to a school for special education needs. Although she showed steady linear growth, she re-
mained shorter than her peers throughout childhood.Other developmental milestones were
also significantly delayed (walking at 2½ yr of age, speech initiation at 3 yr of age). Auditory
testing showed low tone hearing loss (1000–6000 Hz—audible at threshold 20–30 dB, but
reduced hearing at 250 and 500 Hz—audible at threshold 50–60 dB). At 17 yr of age, she
presented to her endocrinologist with absent thelarche and menarche. She reported a nor-
mal sense of smell, and her physical examination revealed bilateral clinodactyly (radial, F5)
and bilateral cutaneous syndactyly (partial fusion, T2–3). She had Tanner II axillary hair and
Tanner IV pubic hair. Biochemical evaluation confirmed hypogonadotropic hypogonadism
(LH: 0.2 IU/L; FSH: 0.8 IU/L; estradiol [E2]: 49 pmol/L [reference range: 55–1284 pmol/L])
with otherwise normal baseline anterior pituitary functions (prolactin, thyroid function tests,
cortisol, and IGF-1). A cranial MRI showed a normal pituitary and intact olfactory structures.
No polymicrogyria was noted and her corpus callosum was normal. Pelvic ultrasound
showed a <1-cm, rudimentary uterus and small ovaries; findings were consistent with an
endocrine diagnosis of normosmic idiopathic hypogonadotropic hypogonadism (nIHH)
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(Seminara and Crowley 2002). After clinical evaluation, sex steroid replacement was initiated,
and the patient responded with appearance of secondary sexual characteristics, a pubertal
growth spurt, and the onset of menses. Her mother had normal menarche at 12 yr of age.
Although the patient was referred to our research program at age of 20 yr, this clinical report
was initiated upon availability of her exome sequencing (ES) results that were performed
more recently. The ES data were available from the index patient and her mother (Fig. 1).
Clinical information and DNA samples from her father and elder sibling were not available.
Literature Review of Reproductive Phenotypes in Previously Reported MS Individuals
First, we reviewed genotypes and phenotypes of previously reported individuals with MS
with RAB3GAP2 pathogenic variants (Table 1). Nine patients (three males, six females;
from four families) were identified (Table 1). Reproductive phenotypes were available in
five individuals (three males and two females). Additionally, treatment and olfactory impair-
ment were not reported in the reviewed literature. All three males were prepubertal at the
time of report, but each had evidence of neonatal hypogonadism during the neonatal period
(i.e., micropenis and/or cryptorchidism). Intriguingly, the reproductive phenotypes noted in
the two female patients (ages 17 yr and 14 yr) were reportedly normal. The genotypic spec-
trum consisted of three homozygous pathogenic missense variants and one homozygous
splice-altering variant. In addition to these genetically defined individuals with MS, we
also reviewed reproductive phenotypes reported in four patients (three males; one female)
without a genetic diagnosis (Supplemental Table 2). Two adult males were reported in the
initial report by Martsolf et al. (1978), both of whom had small testes and clinical testing
showed elevated gonadotropins but with normal testosterone levels (i.e., compensated
hypergonadotropic hypogonadism). Hennekam et al. (1988) reported two patients:
A
D
B C
Figure 1. Pedigree, multiple species alignments of RAB3GAP2 protein, electropherogram, and RAB3GAP2
variants identified to date inWARBM/MS. (A) Pedigree of index patient and segregation of RAB3GAP2 variants
identified in this report; (B) multispecies protein conservation of novelmissense variant (p.Arg428Glu) found in
index individual showing conservation from humans to zebrafish; (C ) electropherograms of variants identified
in this study; and (D) schematic of RAB3GAP2 protein showingMS-associated RAB3GAP2 variants identified in
this report (shown above protein schematic; in green and blue) and RAB3GAP2 variants reported in the liter-
ature (shown below protein schematic). (Red) WARBM-associated variants, (black) MS-associated variants. The
RAB3GAP2 protein domains were defined using Interpro (Mitchell et al. 2019) and Pfam (El-Gebali et al. 2019)
resources.
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a prepubertal boy (age 12 yr) withmicropenis and cryptorchidism and a 17-yr-old femalewith
amenorrhea and biochemical evidence of hypogonadotropic hypogonadism.
Exome Sequencing Analysis and Review of the RAB3GAP2 Allelic Spectrum
in WARBM/MS
The ES data from the index patient were reviewed for known genes reported to cause idio-
pathic hypogonadotropic hypogonadism including genes reported to cause syndromic
forms of IHH (Supplemental Table 1). This analysis identified a c.387-2A>G variant in
RAB3GAP2 (NM_012414.3). This variant had a frequency of 4.1 × 10−06 in gnomAD and
four independent splice prediction programs (Berkeley Drosophila Genome Project
[BDGP], Alternative Splice Site Predictor [ASSP], Mutation Taster, and Human Splicing
Finder) categorized this variant as deleterious secondary to a splicing defect (Table 2).
The proband was also found to harbor a c.1283C>A variant in RAB3GAP2, which predicts
p.(Ala428Glu) (Fig. 1A,B). This variant was novel, disrupted a highly conserved amino acid
residue, and predicted as either deleterious/damaging by multiple prediction programs
(SIFT, PolyPhen, CADD, and REVEL) (Table 2). The splice acceptor (c.387-2A>G) was grad-
ed as pathogenic and the missense variant p.(Arg428Glu) was graded as likely pathogenic
using American College of Medical Genetics (ACMG) guidlines (Richards et al. 2015). In ad-
dition, the proband did not harbor any variants in the coding sequence of other known IHH
genes (Supplemental Table 1). Although her paternal DNA sample was not available for seg-
regation analysis, her mother shared the c.1283C>A p.(Arg428Glu) likely pathogenic vari-
ant but did not harbor the pathogenic splice variant. The likelihood of the essential
splicing variant arising de novo on the maternal haplotype in cis with the p.(Arg428Glu) var-
iant was considered. However, we did not perform additional experiments (cell cloning/
long-range polymerase chain reaction [PCR]) as we deemed that this scenario was unlikely
given the previous clear association of biallelic RAB3GAP2 pathogenic variants with MS.
Hence, it was presumed that the variants were most likely to have been inherited in the com-
pound heterozygous state (Fig. 1C).
We also cataloged all previously reported RAB3GAP2 variants in WARBM/MS (Fig. 1D).
Notably, all WARBM-associated RAB3GAP2 variants were protein-truncating mutations that
have been shown to completely abolish RAB3GAP2 function (Handley et al. 2013; Handley
and Sheridan 2018). In contrast, including this report, all MS-associated RAB3GAP2 variants
were predominantly missense variants or splicing variants that have been deemed to reduce,
but not fully abolish, RAB3GAP2 function.
DISCUSSION
This clinical report highlights the index patient’s clinical odyssey involving multiple diagnos-
tic evaluations without an accurate and timely diagnosis, typifying the clinical challenges
posed to both patients and physicians by such rare clinical syndromes. She presented in in-
fancy to ophthalmology with congenital cataracts, to pediatrics in childhood with apparent
intellectual disability, and subsequently to endocrinology in adolescencewith absent puber-
ty. Eventually, ES identified the two rare variants (pathogenic/likely pathogenic, respectively)
in RAB3GAP2, a gene previously associated wth the WARBM/MS spectrum (Martsolf
et al. 1978; Warburg et al. 1993). The proband had milder phenotypes across the fuller
WARBM/MS spectrum, and hence a diagnosis of RAB3GAP2-related MS was made several
years after her initial clinical presentation, attesting to the utility of genetic testing in provid-
ing a unifying clinical diagnosis in individuals with rare syndromic disorders. Furthermore,
this study is the first longitudinal description of the reproductive phenotypes (pubertal pre-
sentation and biochemical investigations) in an individual with RAB3GAP2-associated MS
RAB3GAP2 mutations in Martsolf syndrome
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wherein we establish hypogonadotropic hypogonadism as a key pathophysiologic defect in
this rare syndrome.
RAB3GAP2 is a GTPase-activating protein, known to form a complex with RAB3GAP1
that together regulates the GTP hydrolysis activity of the Rab protein family of small
GTPase(s) with putative exocytotic roles (Handley and Aligianis 2012). Our observations
that RAB3GAP2-relatedMS is associated with hypogonadotropic hypogonadism are consis-
tent with the previously reported interaction of RAB3GAP2 with rabconnectin 3a, a protein
expressed in exocytosis vesicles in gonadotropin-releasing hormone (GnRH) axonal termi-
nals in the median eminence of the hypothalamus and in the cells expressing luteinizing
hormone (LH) and follicle-stimulating hormone (FSH) within the anterior pituitary gonadotro-
pin-producing cells (Tata et al. 2014, 2017). Therefore, we hypothesize that RAB3GAP2-as-
sociated hypogonadotropic hypogonadismmay also result from defects in hormone release
at the hypothalamic and/or pituitary levels. In that regard, it is notable that the first reported
individual with MS had hyper- (rather than hypo-) gonadotropic hypogonadism, implicating
a primary gonadal defect. To fully establish the precise site of the deficit(s) (hypothalamic vs.
pituitary with or without additional gonadal defects) in RAB3GAP2-relatedWARBM/MS, de-
tailed neuroendocrine studies with GnRH administration will be required, but this was not
available for the patient described in this study. In this regard, it is notable that some genetic
pathways already implicated as causing reproductive disorders are known to disrupt function
at multiple levels across the hypothalamo-pituitary-gonadal axes, resulting in both hyper-
and hypogonadotropic phenotypes (e.g., NROB1/DAX1, Prader–Willi locus, congenital
myotonic dystrophy) (Hamilton et al. 1972; Febres et al. 1975; Muscatelli et al. 1994;
Jadhav et al. 2011; Angulo et al. 2015). Therefore, further longitudinal studies of the repro-
ductive phenotypes along with neuroendocrine studies will be required to fully ascertain the
spectrum of reproductive deficits in WARBM/MS.
It has been hypothesized that the severity of the underlying RAB3GAP2 pathogenic var-
iants (Handley and Aligianis 2012; Handley et al. 2013; Handley and Sheridan 2018) may
determine the resultant clinical phenotypes (severe WARBM vs. milder MS). To date, all re-
ported RAB3GAP2-related WARBM individuals have harbored homozygous, inactivating
variants (frameshifting indels or stop variants). In contrast, the RAB3GAP2-related MS geno-
typic spectrum includes two distinct homozygous missense variants and one homozygous
splice-site variant (Table 1; Fig. 1D). One of the MS-associated missense mutations
(p.Gly1052Cys) was shown to disrupt splicing but produced some preserved full-length pro-
tein with likely residual protein function (Aligianis et al. 2006). Similarly, the second MS-as-
sociated RAB3GAP2 missense variant (p.Arg426Cys) was also deemed not to completely
disrupt RAB3GAP2 protein function (Handley et al. 2013). Experimental data on the precise
consequence of theMS-associated splice variant have not been reported (Gumus 2018). The
MS-associated missense mutation identified in this report (p.Ala428Glu) affects a conserved
amino acid residue, is predicted to be likely pathogenic by ACMG criteria, occurs close to a
previously reported MS-associated variant (p.Arg426Cys), and hence is likely to have re-
duced functional activity without full abrogation of protein function. The essential splice
acceptor variant (c.387-2A>G) identified in this report is predicted to result in an in-frame
deletion (p.Glu130_Arg145del) secondary to skipping of exon 5 of the RAB3GAP2 gene,
with some retained protein function. Thus, in contrast to severe WARBM-associated
RAB3GAP2 variants, almost all of the MS-associated RAB3GAP2 variants (including this re-
port) retain some residual protein function, and these findings lend further support to prior
observations that the severity of the variants underlie genotype–phenotype correlations
(Handley and Aligianis 2012; Handley et al. 2013; Handley and Sheridan 2018). However,
as shown in Table 1, expressivity is still variable across families harboring the less severe
RAB3GAP2 variants, which suggests that there may be other genetic/nongenetic modifiers
that determine the clinical phenotype. In this regard, because our ES analysis was restricted
RAB3GAP2 mutations in Martsolf syndrome
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to genes linked primarily to idiopathic hypogonadotropic hypogonadism, the potential con-
tribution of other genes to the variable phenotypic expressivity could not be examined, and
this represents a limitation of this current study.
A key challenge in accurate and timely diagnosis of complex syndromes relates to “tem-
poral gaps” in the recognition of constituent phenotypes that become evident across the life
span at various developmental stages. For example, in WARBM/MS, congenital cataracts
and neurological features (developmental delay, intellectual disability, and spasticity) are
recognized in early in childhood, whereas reproductive phenotypes are typically not readily
evident in childhood. In this regard, our clinical observation that WARBM/MS is character-
ized by hypogonadotropic hypogonadism is particularly important. It is now established
that the reproductive cascade is paradoxically active in the first fewmonths of life in both sex-
es (Grumbach 2005). During the first 6 mo in boys and ∼12 mo in girls, sex-steroid and go-
nadotropin levels are equivalent to those observed in adulthood, and this developmental
window is referred to as the minipuberty of infancy (Dunkel and Quinton 2014).
Micropenis and/or cryptorchidism (undescended testes) in boysmay be signs of absent mini-
puberty in boys and laboratory assessment of gonadotropin levels at this developmental
window may indicate hypogonadotropic hypogonadism. Indeed, in all of the males with
RAB3GAP2-related MS, evidence of a defective minipuberty was readily evident (micrope-
nis/cryptorchidism) and, thus, in conjunction with other clinical signs, a diagnosis of MS was
feasible (Table 1). Furthermore, recognition of hypogonadotropic hypogonadism in boys
also allows the administration of neonatal testosterone/hCG therapy to help promote penile
growth and alert the observant physician about the need for diligent prospective endocrine
evaluation during adolescence. This recognition helps timely initiation of secondary sexual
characteristics, optimizes adult height/bone health, and avoids much of the psychological
sequalae of delayed puberty. In sharp contrast to boys, disruption of minipuberty in girls
is typically not recognizable as there are no physical signs that are readily evident in infant
girls. Indeed, in the patient described in this report, although ocular/neurological pheno-
types were recognized early, a diagnosis of WARBM/MS was not feasible because hypogo-
nadism, a key defining feature of WARBM/MS, could only be demonstrable at adolescence
when pubertal failure became evident. Hence, in girls presenting with ocular and neurolog-
ical signs of WARBM/MS (and in boys without discernible micropenis/cryptorchidism), ge-
netic testing must be considered to allow an earlier molecular diagnosis of the WARBM/
MS spectrum that will facilitate prospective endocrine evaluations and multidisciplinary in-
volvement including optimal endocrine care and timely initiation of sex-steroid therapy.
In summary, this report illustrates the emerging importance of human genetics and next-
generation sequencing in providing a unifying clinical and molecular diagnosis in rare syn-
dromic presentations of IHH. These combined approaches additionally provide a unique
opportunity to catalog the mutational and phenotypic spectrum of these syndromes and in-
form the pathophysiology, clinical care, and recurrence risk assessments.
METHODS
This research was approved by the Partners Institutional Review Board at the Massachusetts
General Hospital. The family participated in this study after their informed consent was
obtained.
Genetic Analysis
ES was performed at The Broad Institute Genomics Platform. Variant calling was performed
with GATK creating gVCF files for each sample that were then jointly called using the GATK
Genotype gVCF module. Variant quality scores were derived using GATK best practices for
RAB3GAP2 mutations in Martsolf syndrome
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indels and single-nucleotide variants. The jointly called VCF files were then analyzed using
the integrative database framework, GEMINI v.0.19.1. Variant annotation was performed
with the Ensembl Variant Effect Predictor (VEP) against the GRC37/hg19 reference Human
Genome. Rare sequence variants (RSVs) for both homozygous and heterozygous RSVs
were based on a minor allele frequency (MAF) of <0.1% as determined by the genome
Aggregation Database (gnomAD) browser (Karczewski et al. 2019). All RSVs were confirmed
in bidirectional Sanger sequencing in all probands and their pattern of segregation estab-
lished in all available family members. ES coverage for the RAB3GAP2 is shown in Table
3. Sanger sequencing was performed by the Center for Computational and Integrative
Biology (CCIB) DNA Core Facility at Massachusetts General Hospital (Cambridge, MA).
The ES data from the index patient were reviewed for known genes associated with syn-
dromic and nonsyndromic IHH (Supplemental Table 1). The protein domains were defined
using InterPro (Mitchell et al. 2019) and Pfam (El-Gebali et al. 2019) resources.
Literature Review
PubMed was searched for original full-text articles (English language) published up to
November 2019 discussing Martsolf syndrome and RAB3GAP2-associated WARBM/MS.
The search keywords included “Martsolf syndrome,” “Warburg-Micro syndrome,” “pheno-
type,” “genotype,” “RAB3GAP2,” “genetics,” “genemutation,” and “variant.” Relevant ar-
ticles of individuals with MS, genotypes, and endocrine phenotypes were collated.
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